Genfit adds $20M as Ipsen records strong sales for liver drug
Source: SeekingAlpha
2026-02-12 13:52:01 ET
More on Genfit, Ipsen S.A.
- Ipsen S.A. (IPSEY) Q4 2025 Earnings Call Transcript
- Ipsen S.A. 2025 Q4 - Results - Earnings Call Presentation
- Ipsen S.A. (IPSEY) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
- Ipsen S.A. Non-GAAP EPS of €12.09, revenue of €3.68B; sets full-year 2026 guidance and mid-term outlook
- Ipsen rises on FDA breakthrough therapy status for blood cancer therapy
Read the full article on Seeking Alpha
For further details see:
Genfit adds $20M as Ipsen records strong sales for liver drug
Ipsen ADR
NASDAQ: IPSEY
IPSEY Trading
0.0% G/L:
$46.31 Last:
4,394 Volume:
$46.31 Open:
IPSEY Latest News
December 07, 2025 05:33:00 pm
ImCheck Reports Durable Responses and Early Overall Survival Signal with ICT01 in First-line AML at ASH 2025
December 05, 2025 05:00:00 am
ImCheck Announces Oral Presentation of ICT01 First-Line AML Data at the 67th ASH Annual Meeting
June 02, 2025 08:00:00 am
PharmaLogic Announces Appointment of Etienne Montagut as President and Chief Executive Officer
